The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | Future directions for CAR-T therapy in CLL: the potential of combining CAR T-cells with other agents
Tanya Siddiqi, MD, City of Hope National Medical Center, Duarte, CA, shares her thoughts on the future of CAR T-cell therapy for chronic lymphocytic leukemia (CLL), referencing the TRANSCEND-CLL-004 trial (NCT03331198) and the possibility of combining CAR T-cells with other agents such as BTK inhibitors. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
